Kiniksa Pharma Files 2025 Proxy Statement

Ticker: KNSA · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1730430

Kiniksa Pharmaceuticals International, PLC DEF 14A Filing Summary
FieldDetail
CompanyKiniksa Pharmaceuticals International, PLC (KNSA)
Form TypeDEF 14A
Filed DateApr 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

TL;DR

Kiniksa proxy filed, annual meeting June 3rd. Vote your shares!

AI Summary

Kiniksa Pharmaceuticals International, plc filed its definitive proxy statement (DEF 14A) on April 21, 2025, for its annual meeting on June 3, 2025. The filing concerns the company's governance and shareholder matters, with no specific financial transactions or executive compensation details immediately apparent from this initial review.

Why It Matters

This filing provides shareholders with crucial information regarding upcoming votes on company leadership and governance, allowing them to make informed decisions at the annual meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting, not indicating any immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What is the purpose of this DEF 14A filing?

This DEF 14A filing is a definitive proxy statement filed by Kiniksa Pharmaceuticals International, plc for its annual meeting of shareholders.

When was this filing submitted to the SEC?

The filing was submitted on April 21, 2025.

When is the scheduled date for Kiniksa's annual meeting?

The annual meeting is scheduled for June 3, 2025.

What is the company's Standard Industrial Classification (SIC) code?

The SIC code for Kiniksa Pharmaceuticals International, plc is 2834, which corresponds to Pharmaceutical Preparations.

Where is Kiniksa Pharmaceuticals International, plc headquartered?

The company's business and mailing address is listed as 23 Old Bond Street, Floor 3, London, WIS 4PZ.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding Kiniksa Pharmaceuticals International, plc (KNSA).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing